However, the utilization of tumor PD-L1 marker is still in controversy, which is challenged by the highly heterogeneous spatial expression pattern in tumor tissues, highly dynamic changes at different disease stages, and inconvenience of longitudinal tissue sampling owing to the invasive biopsy method (10). The gene discussed is CD274; the disease is neoplasm.